Episode Details

We unpack the MHRA's AI Airlock Sandbox Phase 2 Programme Report to explore how the UK regulator is pressure-testing rules for adaptive algorithms. From generative AI drifting out of scope to algorithms outperforming gold-standard pathologists, learn what happens when modern tech meets traditional regulatory frameworks.

Key points

• Generative AI can drift beyond its intended purpose over time; testing showed out-of-scope performance in approximately 39% of real-world notes without active guardrails.
• Real-world precision for AI systems can be extremely high (e.g., 0.989), which ironically reduces the effectiveness of human oversight as users become complacent.
• When AI diagnostics detect features beyond human capability, such as finding 32% more mitoses than pathologists, regulators face challenges defining the gold standard for performance evaluation.
• Pre-market testing often fails to replicate real-world conditions, making rigorous post-market surveillance essential for lifecycle management.
• Combining multiple low-risk features, like longitudinal memory and personalized biomarker tracking, can inadvertently shift a wellness app into a regulated medical device.
• Predetermined Change Control Plans offer a pathway to safely manage iterative AI updates, provided they are structurally linked to continuous real-world performance monitoring.

Source: AI Airlock Sandbox Phase 2 Programme Report - Medicines and Healthcare products Regulatory Agency, 2026

This spot is available. Reach clinicians, health-system leaders and medtech and pharma teams following AI in medicine. Sponsor the show

This episode is an AI-generated conversation summarising a public document; the hosts' voices are synthetic. It is for information only and is not medical advice. Always refer to the original source.

Full transcript: https://ai-in-medicine-podcast.vercel.app/episodes/inside-the-mhra-ai-airlock-testing-the-boundaries-of-medical-software-def844